Forbes October 6, 2020
Robert Reiss

The pandemic has elevated drug development to become a universal priority. Along the continuum of drug development are the current overlap of its many branches including: biotech, disease research, artificial intelligence, and investment banking — opening the door for a new collaborative model.

So, on September 25, 2020, BERG convened leading stakeholders where I moderated what I believe to be a key step in the pioneering of a new collaborative drug development model. The new series called, the BERG Healthcare Exchange, which will occur quarterly, will focus on key issues and trends impacting the future of healthcare and drug development amid COVID-19 . During the session with top industry experts representing investment, government, big pharma, healthcare delivery, and AI drug...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Biotechnology, Conferences / Podcast, Govt Agencies, Healthcare System, Interview / Q&A, Investments, Pharma, Pharma / Biotech, Provider, Public Health / COVID, Technology, Trends
Related Articles:
Will Synthetic, AI-Based Digital Humans Change Pharma and Life Sciences? Q&A with Abid Rahman, SVP Innovation, EVERSANA
Cerevel Parkinson’s data adds lustre to AbbVie acquisition
Roche Drug Scores Label Expansion for Earlier Use in Lung Cancer
Pharma Pulse 4/19/24: The Health and Healthcare of Gen-Z, Long-Acting Drugs May Revolutionize HIV Prevention/Treatment & more
Recursion, Canaan, Metsera and more—Chutes & Ladders

Share This Article